{
    "organizations": [],
    "uuid": "0073af300284bccb180b582ba6bf644c40380f22",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-initiates-global-phase-3-t/brief-beigene-initiates-global-phase-3-trial-of-anti-pd-1-antibody-tislelizumab-idUSASB0C363",
    "ord_in_thread": 0,
    "title": "BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 44 AM / in 7 minutes BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab Reuters Staff 1 Min Read \nJan 31 (Reuters) - BeiGene Ltd: \n* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:",
    "published": "2018-01-31T13:42:00.000+02:00",
    "crawled": "2018-01-31T13:55:31.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "patient",
        "esophageal",
        "squamous",
        "cell",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}